NCT04986085Completed
Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Nutritional Status of Patients With Gastroenteropancreatic Neuroendocrine Tumors in Spain: NUTRIGETNE
Source: ClinicalTrials.gov · Last updated 28 Mar 2025
Brief summary (registry, in English)
It is well known that the prevalence of malnutrition or risk of malnutrition in cancer patients is high, as well as its impact on different parameters such as hospitalization, survival or response to certain treatments. In patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET), due to their heterogeneity and longer survival, it is expected that the prevalence of malnutrition is probably underdiagnosed, as well as the existence of a negative impact on different parameters (quality of life, survival). So far, the studies carried out on nutrition and NET are very scarce and none has been carried out so far in Spain. Before being able to carry out nutritional intervention studies on these patients, it is necessary to know the reality of the nutritional status of patients with NETs in Spain. The main motivation for the NUTRIGETNE study is to evaluate the epidemiological status of nutrition in NETs in the spanish population. In addition to know the epidemiological picture, it is intended to study the nutritional status from different points of view: analytical, clinical, anthropometric, etc. Besides, the study of nutritional status will allow us to closely monitor the patients who have a higher risk of malnutrition and to propose early interventions for those, as well as the impact of their nutritional status on different parameters: survival, hospitalization, quality of life or responses to the treatments. NUTRIGETNE is a cross-sectional, open and multicenter study in which the nutritional status of patients with GEP NET in Spain will be evaluated.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 399 (actual)
- First submitted
- 22 Mar 2021
- Start date
- 24 Feb 2021
- Primary completion date
- 23 Jan 2024
- Lead sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT04986085
What you commit to
- Study type: Observational
- Participants enrolled: 399
- From 24 Feb 2021 to the primary completion date, 23 Jan 2024
- 16 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who have not signed the informed consent or any situation or condition that compromises the giving of patient voluntary informed consent.
Age
- Patients \<18 or \> 80 years of age.
Other
- Female patients that are currently pregnant.
- Patients with a gastroenteropancreatic neuroendocrine tumor lacking an histopathological diagnosis.
- Patients in palliative treatment or terminal stage.
Who the study is looking for
- Patients diagnosed with a gastroenteropancreatic neuroendocrine tumor by histopathological study.
- Legally capable patients ≥ 18 and ≤ 80 years of age.
- Patients who have signed the informed consent for this study as specified in section 10.3.
- Patients in active treatment: active treatment is considered to be those patients in an advanced stage and in any type of medical treatment (somatostatin analogues, molecular therapies, chemotherapy, radionuclides...), or locoregional therapies.
- Note: Decision was taken to treat the patient with an specific treatment prior and independently of patient inclusion in this non interventional study.
Age in the registry: 18 years to 80 years · Sex: All
Sites (16)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Hospital Universitario Reina Sofia Coordinator of this site? Confirm its status | Córdoba | Spain | Unknown status |
| Hospital Universitario Virgen de la Arrixaca Coordinator of this site? Confirm its status | El Palmar | Spain | Unknown status |
| Hospital Universitario de Cabueñes Coordinator of this site? Confirm its status | Gijón | Spain | Unknown status |
| Hospital Universitario Dr. Josep Trueta Coordinator of this site? Confirm its status | Girona | Spain | Unknown status |
| Hospital Universitario Ramón y Cajal Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario la Princesa Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario La Paz Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario Clínico San Carlos Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario Central De Asturias Coordinator of this site? Confirm its status | Oviedo | Spain | Unknown status |
| Hospital Universitario Marqués de Valdecilla Coordinator of this site? Confirm its status | Santander | Spain | Unknown status |
| Hospital Clínico Universitario de Santiago Coordinator of this site? Confirm its status | Santiago de Compostela | Spain | Unknown status |
| Hospital Universitari i Poliècnic la Fe Coordinator of this site? Confirm its status | Valencia | Spain | Unknown status |
| Institut Valencià d'Oncologia (IVO) Coordinator of this site? Confirm its status | Valencia | Spain | Unknown status |
| Hospital Universitario Miguel Servet Coordinator of this site? Confirm its status | Zaragoza | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.